human plasma β factor xiia fxiia (Innovative Research Inc)
Innovative Research Inc is a verified supplier 
Innovative Research Inc manufactures this product 
93
Structured Review
Innovative Research Inc
human plasma β factor xiia fxiia
Human Plasma β Factor Xiia Fxiia, supplied by Innovative Research Inc, used in various techniques. Bioz Stars score: 93/100, based on 5 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+factor+xiia/Factor+XII+(FXII)+Deficient+Human+Plasma/pm39933826-78-0-15
Average 93 stars, based on 5 article reviews
Human Plasma β Factor Xiia Fxiia, supplied by Innovative Research Inc, used in various techniques. Bioz Stars score: 93/100, based on 5 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+factor+xiia/Factor+XII+(FXII)+Deficient+Human+Plasma/pm39933826-78-0-15
Average 93 stars, based on 5 article reviews
human plasma β factor xiia fxiia - by Bioz Stars,
2026-10
93/100 stars
Images
Related Articles
Activity Assay:Article Title: The putative role of Rhipicephalus microplus salivary serpins in the tick-host relationship Article Snippet: .. To get insight into inhibitory activity of rRmS-3, rRmS-6, and rRmS-17, their protease inhibitory activities were evaluated against a panel of 16 mammalian serine proteases, most of which are related to host defense pathways against tick feeding (the amount of protease used is give in parenthesis): bovine thrombin (43 U), pancreatic porcine elastase (21.6 nM), pancreatic bovine trypsin (24.6 nM), pancreatic bovine α-chymotrypsin (96 nM), pancreatic porcine kallikrein (33 U), human chymase (10 U), human tryptase (10 U), human plasmin (10 nM) (Sigma-Aldrich, St. Louis, MO, USA), human neutrophil cathepsin G (166 nM) (Enzo Life Sciences Inc., Farmingdale, NY, USA), human factor XIa (3.68 nM), bovine factor IXa (306 nM), Produced:Article Title: A novel genetically-encoded bicyclic peptide inhibitor of human urokinase-type plasminogen activator with better cross-reactivity toward the murine orthologue. Article Snippet: .. Final concentrations of serine proteases were the following: human uPA (UPALMW, from human urine, 33 kDa; Molecular Innovations, Novi, MI, USA) 1.5 nM, mouse uPA (MUPA-LMW, recombinantly produced in insect cells, 31 kDa; Molecular Innovations, Novi, MI, USA) 12 nM, human tPA (HTPATC, recombinant, 70 kDa; Molecular Innovations, Novi, MI, USA) 7.5 nM, mouse tPA (MTPA, recombinantly produced in insect cells, 70 kDa; Molecular Innovations, Novi, MI, USA) 6 nM, human trypsin (HTRYP, from human pancreas, 25 kDa; Molecular Innovations, Novi, MI, USA) 0.05 nM, human plasmin (HPLM, from human plasma, 85 kDa; Molecular Innovations, Novi, MI, USA) 1.5 nM, human plasma kallikrein (IHPKA, from human plasma, 86 kDa; Innovative Research, Novi, MI, USA) 0.5 nM, human thrombin (IHT, from human plasma, 37 kDa, Innovative Research, Novi, MI, USA) 10 nM, Recombinant:Article Title: A novel genetically-encoded bicyclic peptide inhibitor of human urokinase-type plasminogen activator with better cross-reactivity toward the murine orthologue. Article Snippet: .. Final concentrations of serine proteases were the following: human uPA (UPALMW, from human urine, 33 kDa; Molecular Innovations, Novi, MI, USA) 1.5 nM, mouse uPA (MUPA-LMW, recombinantly produced in insect cells, 31 kDa; Molecular Innovations, Novi, MI, USA) 12 nM, human tPA (HTPATC, recombinant, 70 kDa; Molecular Innovations, Novi, MI, USA) 7.5 nM, mouse tPA (MTPA, recombinantly produced in insect cells, 70 kDa; Molecular Innovations, Novi, MI, USA) 6 nM, human trypsin (HTRYP, from human pancreas, 25 kDa; Molecular Innovations, Novi, MI, USA) 0.05 nM, human plasmin (HPLM, from human plasma, 85 kDa; Molecular Innovations, Novi, MI, USA) 1.5 nM, human plasma kallikrein (IHPKA, from human plasma, 86 kDa; Innovative Research, Novi, MI, USA) 0.5 nM, human thrombin (IHT, from human plasma, 37 kDa, Innovative Research, Novi, MI, USA) 10 nM, Clinical Proteomics:Article Title: A novel genetically-encoded bicyclic peptide inhibitor of human urokinase-type plasminogen activator with better cross-reactivity toward the murine orthologue. Article Snippet: .. Final concentrations of serine proteases were the following: human uPA (UPALMW, from human urine, 33 kDa; Molecular Innovations, Novi, MI, USA) 1.5 nM, mouse uPA (MUPA-LMW, recombinantly produced in insect cells, 31 kDa; Molecular Innovations, Novi, MI, USA) 12 nM, human tPA (HTPATC, recombinant, 70 kDa; Molecular Innovations, Novi, MI, USA) 7.5 nM, mouse tPA (MTPA, recombinantly produced in insect cells, 70 kDa; Molecular Innovations, Novi, MI, USA) 6 nM, human trypsin (HTRYP, from human pancreas, 25 kDa; Molecular Innovations, Novi, MI, USA) 0.05 nM, human plasmin (HPLM, from human plasma, 85 kDa; Molecular Innovations, Novi, MI, USA) 1.5 nM, human plasma kallikrein (IHPKA, from human plasma, 86 kDa; Innovative Research, Novi, MI, USA) 0.5 nM, human thrombin (IHT, from human plasma, 37 kDa, Innovative Research, Novi, MI, USA) 10 nM, Article Title: Combination of Coevolutionary Information and Supervised Learning Enables Generation of Cyclic Peptide Inhibitors with Enhanced Potency from a Small Data Set Article Snippet: .. Final concentrations of serine proteases were the following: human uPA (UPA-LMW, Molecular Innovations, Novi, MI, USA) 1.5 nM, mouse uPA (MUPA-LMW, Molecular Innovations, Novi, MI, USA) 12 nM, human tPA (HTPATC; Molecular Innovations, Novi, MI, USA) 7.5 nM, mouse tPA (MTPA, Molecular Innovations, Novi, MI, USA) 6 nM, human trypsin (HTRYP, Molecular Innovations, Novi, MI, USA) 0.05 nM, human plasmin (HPLM, Molecular Innovations, Novi, MI, USA) 1.5 nM, human plasma kallikrein (IHPKA, Innovative Research, Novi, MI, USA) 0.5 nM, human thrombin (IHT, Innovative Research, Novi, MI, USA) 10 nM, and |